Difference between revisions of "Doxepine-fluoxetine"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = fluoxetine  
 
| to = fluoxetine  
 
| stop =  
 
| stop =  
* '''Before day 1:''' gradually reduce dosage of doxepin to a maximum of 100 mg/day.
+
{{downDoxepin}}
* '''Day 1:''' reduce dosage of doxepin to 50 mg/day.
 
* '''Day 3:''' reduce dosage of doxepin to 25 mg/day.
 
* '''Day 8:''' stop administration of doxepin.
 
 
| start =  
 
| start =  
* '''Day 8:''' start administration of fluoxetine in a normal dosage of 20 mg/day.
+
* '''Day 9:''' start administration of fluoxetine in a normal dosage of 20 mg/day.
 
| info =  
 
| info =  
 
* {{theorSS}}
 
* {{theorSS}}
 
* Fluoxetine is a strong inhibitor of CYP2D6, which metabolizes doxepin.  }}
 
* Fluoxetine is a strong inhibitor of CYP2D6, which metabolizes doxepin.  }}

Revision as of 13:24, 2 November 2015

Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin
Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine

Switch medication from doxepin to fluoxetine.[2] [3]

Nietinrijdenbord.png Stop doxepin
  • Before day 1: gradually reduce dosage of doxepin to a maximum of 100 mg/day.
  • Day 1: reduce dosage of doxepin to 50 mg/day.
  • Day 3: reduce dosage of doxepin to 25 mg/day.
  • Day 8: stop administration of doxepin.
Eenrichtingbord.png Start fluoxetine
  • Day 9: start administration of fluoxetine in a normal dosage of 20 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Fluoxetine is a strong inhibitor of CYP2D6, which metabolizes doxepin.
  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2023; Monografie "doxepine" (Dutch)
  2. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  3. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.